Author(s): Kwara A, Flanigan TP, Carter EJ, Kwara A, Flanigan TP, Carter EJ
Abstract Share this page
Abstract The overlapping epidemiology of human immunodeficiency virus (HIV) infection and tuberculosis (TB) and the catastrophic consequences of the interactions between the two epidemics have led to increased morbidity and mortality due to HIV-associated TB. While effective therapy is available for both conditions, there are major challenges in the concurrent treatment of HIV and TB co-infection. This review examines the interactions between HIV and TB infections and reviews the current status of highly active antiretroviral therapy (HAART) in patients with co-infection. Specific questions relating to optimal timing of concurrent HAART, challenges to concurrent HAART, optimal regimens and future considerations are discussed.
This article was published in Int J Tuberc Lung Dis
and referenced in Journal of AIDS & Clinical Research